ADOLFO JOSE
LOPEZ DE MUNAIN ARREGUI
PROFESORADO ASOCIADO
![Foto de ADOLFO JOSE](/img/nophoto.png)
![Foto de Universitat de València](/img/noimage_org.png)
Universitat de València
Valencia, EspañaPublicaciones en colaboración con investigadoras/es de Universitat de València (10)
2023
-
Analysis of muscle magnetic resonance imaging of a large cohort of patient with VCP-mediated disease reveals characteristic features useful for diagnosis
Journal of Neurology, Vol. 270, Núm. 12, pp. 5849-5865
2022
-
Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome
Annals of Clinical and Translational Neurology, Vol. 9, Núm. 2, pp. 122-131
2021
-
Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy
Molecular Therapy - Nucleic Acids, Vol. 26, pp. 174-191
2019
-
Increased Muscleblind levels by chloroquine treatment improve myotonic dystrophy type 1 phenotypes in in vitro and in vivo models
Proceedings of the National Academy of Sciences of the United States of America, Vol. 116, Núm. 50, pp. 25203-25213
2017
-
Distribution and genotype-phenotype correlation of GDAP1 mutations in Spain
Scientific Reports, Vol. 7, Núm. 1
2016
-
Identification and Characterization of the Dermal Panniculus Carnosus Muscle Stem Cells
Stem Cell Reports, Vol. 7, Núm. 3, pp. 411-424
-
Six serum miRNAs fail to validate as myotonic dystrophy type 1 biomarkers
PLoS ONE, Vol. 11, Núm. 2
2014
-
Murine muscle engineered from dermal precursors: An in vitro model for skeletal muscle generation, degeneration, and fatty infiltration
Tissue Engineering - Part C: Methods, Vol. 20, Núm. 1, pp. 28-41
2013
-
Expanded CTG repeats trigger miRNA alterations in Drosophila that are conserved in myotonic dystrophy type 1 patients
Human Molecular Genetics, Vol. 22, Núm. 4, pp. 704-716